Genovis AB
GENO
Rank in Stocks
#18189
Genovis AB (publ.) develops and sells tools for the development of new... Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues. In addition, the company offers OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; OpeRATOR, an O-glycan-specific protease; ImpaRATOR, an O-glycan-dependent protease; OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; and GlycOCATCH, an affinity resin. Further, it provides GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a family of antibody products; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody, as well as SEQURNA RNase Inhibitor Thermostable. Additionally, the company offers antibodies, proteins, antigens, kits, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services. It serves biotech and pharmaceutical, contract research, and contract manufacturing companies. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.
Share Price
$2.14
Last synced: 2026-11-09
Market Cap
$141.54M
Change (1 day)
0.44%
Change (1 year)
-1.15%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Genovis AB (GENO)
Category
Healthcare
Operating Margin for Genovis AB (GENO)
Operating Margin as of November 2026 TTM: 14.78%
According to Genovis AB's latest financial reports, its current operating margin (TTM) is 14.78%. At the end of 2025 the company had an operating margin of 21.32%.
Operating Margin history for Genovis AB from 2008 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 14.78% | -30.68% |
| 2025 | 21.32% | -39.22% |
| 2024 | 35.08% | 2.36% |
| 2023 | 34.27% | 55.99% |
| 2022 | 21.97% | -16.75% |
| 2021 | 26.39% | 133.95% |
| 2020 | 11.28% | -49.51% |
| 2019 | 22.34% | -903.60% |
| 2018 | -2.78% | -91.89% |
| 2017 | -34.26% | -56.99% |
| 2016 | -79.66% | -46.68% |
| 2015 | -149.41% | -39.77% |
| 2014 | -248.07% | 38.30% |
| 2013 | -179.37% | -45.95% |
| 2012 | -331.89% | -31.04% |
| 2011 | -481.28% | -31.62% |
| 2010 | -703.85% | -44.71% |
| 2009 | -1,272.96% | -80.99% |
| 2008 | -6,695.57% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -97.39% |
US
|
|
| -149.01% | -110.08% |
US
|
|
| 25.57% | -98.27% |
AU
|
|
| 31.23% | -97.89% |
BE
|
|
| 29.35% | -98.01% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Genovis AB's operating margin
What is Genovis AB's operating margin?
Genovis AB's operating margin is 14.78%, as of Nov 2026.
What was Genovis AB's operating margin in 2025?
In 2025, Genovis AB's operating margin was 21.32%, compared with 35.08% in 2024.
How has Genovis AB's operating margin changed since 2020?
From 2020 to 2025, Genovis AB's operating margin was highest in 2024 (35.08%) and lowest in 2020 (11.28%).
How does Genovis AB's operating margin compare with similar companies?
Genovis AB's operating margin (14.78%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.